截至2024年年报，中国抗体-B营业总收入202.6万元、净利润-1.85亿元。 8月15日，中国抗体-B(03681)盘中上涨9.57%，截至14:56，报3.55元/股，成交1.38亿元。 中国抗体制药有限公司专注于研发、生产和商业化基于单克隆抗体的生物制剂来治疗免疫性疾病，其中 旗舰产品SM03 (Suciraslimab) 是全球首款用于治疗类风湿关节炎的抗CD22单抗药物，正在全速进行商 业化进程。公司的其他关键数据包括2023年4月其SM03 (Suciraslimab)在中国进行治疗类风湿关节炎的 III期临床研究完成，并且在同年9月5日获得国家药品监督管理局接受其治疗类风湿关节炎的生物制品许 可申请，其生产基地在2024年1月完成了临床现场检查和生产质量管理规范检查。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The cooperation is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic cooperation as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The collaboration is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The cooperation will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic partnership as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company has entered into a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that this cooperation provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The agreement is seen as fair and reasonable, aligning with the overall interests of the company and its shareholders [1] Group 2: Objectives and Framework - The cooperation aims to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] - The project-driven model will focus on resource sharing and efficient communication, allowing the company to utilize the advanced laboratory facilities, animal supply resources, and valuable data assets of the Sun Yat-sen University Hong Kong Advanced Institute [1] - This strategic partnership is expected to create a mutually beneficial framework that supports growth and ensures long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute of Science (SYSU-IAS) to enhance joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation agreement aims to leverage the strengths of both parties to accelerate the development of innovative drugs and facilitate the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model focusing on resource sharing and efficient communication [1] Group 2: Resource Utilization - The partnership allows the company to directly utilize SYSU-IAS's comprehensive laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets [1] - These elements are considered key factors in promoting innovative drug research and ensuring the sustainable development of the company's R&D efforts [1]

Core Viewpoint - A comprehensive strategic cooperation agreement has been signed between China Antibody and the Hong Kong Advanced Institute of Zhongshan University, aiming to integrate research and industrial resources to advance biopharmaceutical innovation and clinical translation for better treatment options for global patients [3][4]. Group 1: Cooperation Agreement Details - The cooperation agreement includes five key areas: joint research, shared facility resources, full-chain technical support, drug development, and training and knowledge exchange [3]. - The collaboration aims to enhance professional research capabilities in treating degenerative diseases through training programs and personnel exchanges [3][4]. Group 2: Institutional Goals and Capabilities - The Hong Kong Advanced Institute of Zhongshan University focuses on addressing global medical challenges and aims to precisely connect research resources with industrial strengths [4]. - The institute possesses strong capabilities in animal model construction, regulatory expertise, and joint laboratory facilities, which will synergize with China Antibody's practical experience in antibody drug development [4]. - Established in October of the previous year, the institute integrates teaching, research, and technology transfer, with a focus on biomedicine, applied mathematics, and interdisciplinary humanities and social sciences [4].

Major Events - Kangji Medical (09997) received a privatization offer at a premium of approximately 9.9% [1] - China Resources Pharmaceutical (03320) plans to participate in the establishment of a fund [1] - Ganfeng Lithium (01772) intends to jointly integrate a joint venture with LAR to develop the Pozuelos-Pastos Grandes salt lake basin in Argentina [1] - China Antibody-B (03681) signed a comprehensive strategic cooperation agreement with the Hong Kong Advanced Institute of Research at Sun Yat-sen University [1] - Mingyuan Cloud (00909) plans to acquire 100% equity of ASIOT Corporation for 700 million yen [1] - Weilu Group (01196) experienced unusual stock price and trading volume changes and is in preliminary discussions with an independent third party regarding a potential acquisition of mobile game rights [1] Operating Performance - China Unicom (00762) reported revenue exceeding 200 billion yuan in the first half of the year, with a profit attributable to equity holders of 14.484 billion yuan, a year-on-year increase of 5.01% [1] - China Unicom (00762) had approximately 1.208 billion cumulative "Ubiquitous Intelligent Connection" users in the second quarter [1] - Tencent Music (01698) achieved double growth in revenue and profit in the first half of the year, with a profit attributable to equity holders of 6.7 billion yuan, a year-on-year increase of 115.85% [1] - Galaxy Entertainment (00027) reported a mid-term profit attributable to shareholders of 5.24 billion HKD, a year-on-year increase of 19.44% [1] - WH Group (00288) reported a mid-term profit attributable to shareholders of 788 million USD, a year-on-year increase of 0.51%, with an interim dividend of 0.2 HKD per share [1] - Minmetals Resources (01208) reported a mid-term profit attributable to equity holders of 340 million USD, a year-on-year increase of 1511% [1] - China Literature Group (00772) reported a mid-term profit attributable to shareholders of 850 million yuan, a year-on-year increase of 68.5% [1] - Hong Kong Electric (02638) reported a mid-term profit attributable to unit holders of 1.001 billion HKD, a year-on-year increase of 5.7% [1] - 361 Degrees (01361) reported a mid-term profit attributable to equity holders of 858 million yuan, a year-on-year increase of 8.6% [1] - Eagle Precision (01286) reported a mid-term profit attributable to equity holders of 346 million HKD, a year-on-year increase of 13.7% [1] - China Everbright Water (01857) reported a mid-term profit attributable to equity holders of 564 million HKD, a year-on-year decrease of 2.99% [1] - FIT HON TENG (06088) reported a mid-term profit attributable to shareholders of 31.511 million USD, a year-on-year decrease of 3.11% [1] - China Lilang (01234) reported a mid-term profit attributable to equity holders of 243 million yuan, a year-on-year decrease of 13.4% [1] - Fudan Zhangjiang (01349) reported a mid-term profit attributable to shareholders of 5.715 million yuan, a year-on-year decrease of 91.89% [1] - Wharf Holdings (00004) reported a mid-term profit attributable to shareholders of 535 million HKD, returning to profitability [1] - China Resources Land (01109) reported a cumulative contract sales amount of approximately 123.6 billion yuan for the first seven months, a year-on-year decrease of 11.8% [1]

Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute (SYSU-IAS) to conduct joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation agreement aims to leverage the combined strengths of the company and SYSU-IAS to accelerate the development of innovative drugs and facilitate the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This strategic partnership is expected to provide the company direct access to SYSU-IAS's comprehensive laboratory facilities, animal supply resources (especially non-primate animals), and valuable data assets, which are critical for advancing drug research and ensuring sustainable development [1] Group 2: Long-term Growth and Sustainability - The board of directors believes that this strategic cooperation establishes a mutually beneficial framework that will help drive growth and ensure long-term sustainability [1] - The collaboration aligns with the company's strategy to advance its innovative drug portfolio [1]

中国抗体-B(03681)发布公告，于2025年8月12日，公司与中山大学香港高等研究院有限公司(中山大学香 港高等研究院或SYSU-IAS)(连同公司统称订约方)订立全面战略合作协议(合作协议)，据此，订约方同 意开展为期三年的合作，以于生物医学领域进行联合研发。 本合作协议旨在借助公司与中山大学香港高等研究院的联合优势，加速创新药物的发展，并推动全球范 围内科研成果向临床应用的转化。该合作将以项目驱动模式开展，以资源共享及高效沟通为核心框架。 该模式将使集团可直接利用中山大学香港高等研究院完备的实验室设施、实验动物供应资源(尤其非灵 长类动物)和宝贵的数据资产，此乃推动创新药研以及公司研发可持续发展的关键要素。董事会认为此 项战略合作构建了一个互利共赢的框架，有助于推动增长并确保长期可持续性。此次合作与公司推进其 在研创新药组合的发展战略相符。 中山大学香港高等研究院是中山大学设立的研究机构，于2024年2月8日在香港成立。研究院致力于高端 学术研究、跨学科合作，并促进中国内地与香港在科技、人文等领域的交流与合作。 ...

本合作协议旨在借助公司与中山大学香港高等研究院的联合优势，加速创新药物的发展，并推动全球范 围内科研成果向临床应用的转化。该合作将以项目驱动模式开展，以资源共享及高效沟通为核心框架。 该模式将使集团可直接利用中山大学香港高等研究院完备的实验室设施、实验动物供应资源(尤其非灵 长类动物)和宝贵的数据资产，此乃推动创新药研以及公司研发可持续发展的关键要素。董事会认为此 项战略合作构建了一个互利共赢的框架，有助于推动增长并确保长期可持续性。此次合作与公司推进其 在研创新药组合的发展战略相符。 董事会认为，合作协议为双方提供了宝贵的机会，使其能够充分发挥各自的资源和专业知识，实现互利 共赢并产生协同效应。因此，董事会认为订立合作协议属公平合理，并符合公司及其股东的整体利益。 联合研究工作：订约方将利用彼此的专业知识联合开展科学研究，包括发现研究、靶点阐释及严重疾病 动物模型开发；中山大学香港高等研究院应负责为该等联合研究提供实验场地和动物。 设施共用：中山大学香港高等研究院应允许本公司使用其位于中国内地深圳市深圳福田国际生物医药产 业园的实验室，以进行联合科学研究。实验室应被正式指定为"中山大学香港高等研究院—中国抗 ...